Brian Gilger

Bio

Dr. Brian Gilger is a native of Akron, Ohio, USA. After an internship and residency in ophthalmology, he joined The Ohio State University as an Assistant Professor of Ophthalmology in 1992. In October of 1995, Dr. Gilger joined the faculty at North Carolina State University College of Veterinary Medicine as an Associate Professor of Ophthalmology and is now a Professor of Ophthalmology. Dr. Gilger is particularly interested in ocular diseases of horses and is the editor and author of three editions of the textbook, Equine Ophthalmology. He has over 130 peer reviewed scientific publications, over 30 book chapters, and has research interests in ocular drug delivery, immunology, pharmacology, and toxicology.

EDUCATION

Doctor of Veterinary Medicine, The Ohio State University; 1987
Internship, The Animal Medical Center, NY, NY; 1987-88
Residency in Ophthalmology, Auburn University; 1989-1992
Masters of Science, Auburn University; 1992

AFFILIATIONS

American Veterinary Medical Association, Member, 1987–present
Association for Research in Vision and Ophthalmology, Member, 1989–present
Fellow, 2016 – present
American College of Veterinary Ophthalmologists, Diplomate and Member, 1993–present
International Equine Ophthalmology Consortium, Member, 2009-present
North Carolina Veterinary Medical Association, Member, 1995 – present
American Society of Toxicology (SOT); 2013 – present
Councilor – Ocular Toxicology Specialty Section, 2014 – present
American Board of Toxicology, Diplomate, 2008-present

CERTIFICATIONS

Diplomate, American College of Veterinary Ophthalmologists

Area(s) of Expertise

BIOLOGICAL BARRIERS, PHARMACOLOGY
Ophthalmology

Publications

• A chimeric anti-vascularization immunomodulator prevents high-risk corneal transplantation rejection via ex vivo gene therapy , MOLECULAR THERAPY (2024)
• Causes, treatment, and outcome of hyphema, fibrin, and vitreal hemorrhage in horses: 219 cases (2012–2023) , Journal of the American Veterinary Medical Association (2024)
• Cold atmospheric plasma inactivates Aspergillus flavus and Fusarium keratoplasticum biofilms and conidia in vitro , JOURNAL OF MEDICAL MICROBIOLOGY (2024)
• Current therapy and advancements in the treatment of equine fungal keratitis , Journal of the American Veterinary Medical Association (2024)
• Ocular toxicity, distribution, and shedding of intravitreal AAV-eqIL-10 in horses , MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT (2024)
• Relationship between stable management practices and ocular disease in horses , EQUINE VETERINARY EDUCATION (2024)
• Treatment of equine keratomycosis, part 1: selection of appropriate therapy based on clinical presentation and diagnostic testing improves clinical outcomes , Journal of the American Veterinary Medical Association (2024)
• Treatment of equine keratomycosis, part 2: reporting common systemic and ocular complications to enhance decision-making for equine clinicians and owners , Journal of the American Veterinary Medical Association (2024)
• Ultrasound biomicroscopic imaging parameters associated with outcome in equine infectious ulcerative keratitis and stromal abscesses , Journal of the American Veterinary Medical Association (2024)
• AAV-mediated expression of HLA-G for the prevention of experimental ocular graft vs. host disease , Molecular Therapy - Methods & Clinical Development (2023)

View all publications